Rusmik Oza

Yes, hi. My question was that we are very focused on diabetes. So, beyond diabetes, is there any initiative to get into any new segment of the Indian market? And can this 14% growth which we saw in last quarter, will this be sustainable in the next two quarters till the end of this calendar year?

Thanks. One more question was that, are there any identified products from the parent's basket which can be brought into India going forward based on whatever internal discussions we have with our parent?

Okay, and a last question, sir, before the demerger, the payout ratio used to be quite healthy. So, going forward also can we expect the payout ratio to be dividend payout ratio to be closer to the yearly earnings number?